Présentation de l'entreprise
Inventiva S.A. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of oral small molecule therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and various other medical conditions across France and international markets. The company functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by significant research and development expenditures and a reliance on successful clinical trial outcomes to achieve product approval and market entry. Its current scale is defined by a market capitalization of $1.10 billion, while annual revenue over the trailing twelve months stands at $7.93 million, with an employee count listed as unavailable in current public filings. These financial dimensions indicate that Inventiva holds a mid-cap status within the biotechnology landscape, suggesting a company that has achieved substantial valuation based on its pipeline potential rather than established profitable operations, a common trajectory for entities focusing on late-stage asset development before generating significant commercial cash flows.
Santé financière
The company reported revenue of $7.93 million for the trailing twelve months, contrasted against a net income loss of $-354,137,984 and an EBITDA of $-138,856,000, revealing a cost structure where expenses, particularly those related to research, development, and operational overhead, vastly exceed current revenue generation. While the specific figures for free cash flow are not disclosed in the available data, the negative EBITDA suggests limited financial flexibility typical of pre-revenue or early commercial-stage biopharmaceutical companies that must deplete capital reserves to fund ongoing clinical programs. The gross margin is reported at 100.0%, indicating that the cost of goods sold is currently negligible relative to sales, likely due to the early stage of product commercialization where inventory costs have not yet accumulated. Conversely, the operating margin stands at -3686.1% and the profit margin at 0.0%, figures that highlight an aggressive burn rate where operating expenses are disproportionately high compared to the modest sales base. Regarding the balance sheet, specific data points for total cash, total debt, and the debt-to-equity ratio are unavailable, preventing a direct comparison of liquidity against leverage, though the negative price-to-book ratio of -72.28 often correlates with asset-heavy or highly speculative valuation models in biotech. Similarly, the current ratio, return on equity, and return on assets are not reported as N/A, meaning standard liquidity and return efficiency metrics cannot be calculated or verified at this time.
Évaluation de la valorisation
The valuation metrics present a complex picture, with a trailing P/E ratio marked as N/A due to the lack of positive earnings, while the forward P/E is listed at -4.17, a figure that implies the market is pricing in negative future earnings or is utilizing an alternative denominator method for companies not yet profitable. The price-to-book ratio is reported at -72.28, a negative valuation multiple that indicates the market is pricing the company's equity at a significant discount relative to its book value, a scenario often seen when liabilities outweigh assets on the balance sheet or when intangible assets like pipeline value are not fully captured on the books. The price-to-sales ratio stands at 138.85, suggesting the market is willing to pay a substantial premium for every dollar of revenue, reflecting high expectations for future product launches and successful clinical outcomes rather than current profitability. The enterprise value to EBITDA multiple is N/A, further underscoring the difficulty in applying traditional valuation multiples to a company with negative or negligible earnings power. In terms of trading range, the stock has fluctuated between a 52-week high of $7.98 and a 52-week low of $2.85, placing the current valuation context within a wide band of volatility typical for small-cap biotechnology firms. The beta of 0.95 indicates that the stock's price volatility is roughly in line with the broader market, suggesting it does not exhibit extreme sensitivity to general market movements despite its specific sector risks.
Growth & Income
Revenue growth year-over-year is reported at -79.6%, indicating a contraction in sales, while earnings growth is N/A due to the absence of prior period profitability; this disparity implies that the company is currently in a phase of scaling down sales or managing a transition that is impacting its top line before revenue can eventually support profit generation. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all available earnings, or in this case, capital resources, are being reinvested into research and development activities rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize advancing their pipeline, such as Lanifibranor, over returning capital, thereby sacrificing immediate income for potential long-term value creation. Consequently, the overall growth and income profile for Inventiva S.A. is characterized by negative revenue growth and zero dividend income, positioning the asset as a pure-play investment reliant entirely on the successful commercialization of its therapeutic candidates to alter its financial trajectory.